Any regulatory changes to drug patents and pricing should be wary of stifling innovation, writes Neal Gerber Eisenberg lawyer Thomas Campbell | 3mos
Thomas Campbell is a patent and trademark prosecution partner at Neal Gerber Eisenberg
Any regulatory changes to drug patents and pricing should be wary of stifling innovation, writes Neal Gerber Eisenberg lawyer Thomas Campbell | 3mos